Home > Insider Trading > Filing (0001365618-16-000007)

Filing Details

Accession Number:: 0001365618-16-000007
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-04-11 16:33:06
Reporting Period:: 2016-04-07

Filing Date:: 2016-04-11
Accepted Time:: 2016-04-11 16:33:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1411158	Anacor Pharmaceuticals Inc.	ANAC	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1365618	D Anders Hove	C/O Venrock 3340 Hillview Ave. Palo Alto CA 94304		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-04-07	102,760	$70.33	222,775	No	4	S	Indirect	By Funds and LLC's
Common Stock	Disposition	2016-04-07	99,981	$71.44	122,794	No	4	S	Indirect	By Funds and LLC's
Common Stock	Disposition	2016-04-07	13,000	$72.15	109,794	No	4	S	Indirect	By Funds and LLC's
Common Stock	Disposition	2016-04-07	2,272	$73.29	107,522	No	4	S	Indirect	By Funds and LLC's
Common Stock	Disposition	2016-04-07	200	$74.13	107,322	No	4	S	Indirect	By Funds and LLC's
Common Stock	Disposition	2016-04-07	6,820	$75.57	100,502	No	4	S	Indirect	By Funds and LLC's
Common Stock	Disposition	2016-04-08	3,868	$70.05	96,634	No	4	S	Indirect	By Funds and LLC's
Common Stock	Disposition	2016-04-08	400	$71.40	96,234	No	4	S	Indirect	By Funds and LLC's

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Funds and LLC's
No	4	S	Indirect	By Funds and LLC's
No	4	S	Indirect	By Funds and LLC's
No	4	S	Indirect	By Funds and LLC's
No	4	S	Indirect	By Funds and LLC's
No	4	S	Indirect	By Funds and LLC's
No	4	S	Indirect	By Funds and LLC's
No	4	S	Indirect	By Funds and LLC's

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	33,886	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Venrock Healthcare Capital Partners, L.P. ("VHCP"), VHCP Co-Investment Holdings, LLC ("VHCP Co-Invest"), Venrock Associates IV, L.P. ("VA4"), Venrock Partners, L.P. ("VP") and Venrock Entreprenerus Fund IV, L.P. ("VEF4") on March 16, 2016.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) - (18) to this Form 4.
The shares are held as follows: 102,931 shares held by VA4, 20,991 shares held by VP, 2,529 shares held by VEF4, 81,429 shares held by VHCP and 14,895 shares held by VHCP Co-Invest.
Venrock Management IV, LLC ("VM4"), Venrock Partners Management, LLC ("VPM") and VEF Management IV, LLC ("VEFM4") are the sole general partners of VA4, VP and VEF4, respectively, and may be deemed to beneficially own these shares. VHCP Management, LLC ("VHCP Management") is the general partner of VHCP and the manager of VHCP Co-Invest and may be deemed to beneficially own these shares. Anders Hove is a member of VM4, VPM and VEFM4 and a managing member of VHCP Management. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP, VEF4, VHCP, VHCP Co-Invest, VM4, VPM, VEFM4 and VHCP Management except to the extent of his indirect pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive.
The shares are held as follows: 56,736 shares held by VA4, 11,570 shares held by VP, 1,394 shares held by VEF4, 44,884 shares held by VHCP and 8,210 shares held by VHCP Co-Invest.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.96, inclusive.
The shares are held as follows: 50,729 shares held by VA4, 10,345 shares held by VP, 1,247 shares held by VEF4, 40,132 shares held by VHCP and 7,341 shares held by VHCP Co-Invest.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.03 to $73.88, inclusive.
The shares are held as follows: 49,679 shares held by VA4, 10,131 shares held by VP, 1,221 shares held by VEF4, 39,302 shares held by VHCP and 7,189 shares held by VHCP Co-Invest.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.11 to $74.16, inclusive.
The shares are held as follows: 49,587 shares held by VA4, 10,113 shares held by VP, 1,218 shares held by VEF4, 39,228 shares held by VHCP and 7,176 shares held by VHCP Co-Invest.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.17 to $75.84, inclusive.
The shares are held as follows: 46,436 shares held by VA4, 9,470 shares held by VP, 1,141 shares held by VEF4, 36,735 shares held by VHCP and 6,720 shares held by VHCP Co-Invest.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive.
The shares are held as follows: 44,649 shares held by VA4, 9,106 shares held by VP, 1,097 shares held by VEF4, 35,321 shares held by VHCP and 6,461 shares held by VHCP Co-Invest.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.39 to $71.41, inclusive.
The shares are held as follows: 44,464 shares held by VA4, 9,068 shares held by VP, 1,092 shares held by VEF4, 35,175 shares held by VHCP and 6,435 shares held by VHCP Co-Invest.
The reporting person is a member of VR Management, LLC (the "Management Company"). Under an agreement between the reporting person and the Management Company, the reporting person is deemed to hold an aggregate of 794 of the reported securities for the sole benefit of the Management Company (the "Management Company Shares"). The Management Company may be deemed the indirect beneficial owner of the Management Company Shares, and the reporting person may be deemed the indirect beneficial owner of the Management Company Shares through his interest in the Management Company. The reporting person disclaims beneficial ownership of the Management Company Shares except to the extent of his indirect pecuniary interest therein.